|Bid||202.76 x 900|
|Ask||203.00 x 1000|
|Day's range||199.50 - 214.97|
|52-week range||49.09 - 252.78|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||194.62|
What happened BioNTech (NASDAQ: BNTX) shares were having an atypically bad day on Wednesday, and by the close of trading were down by nearly 7%. A downshift in one analyst's recommendation seems to be the latest headwind buffeting the company's stock.
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.
The big drugmaker's bottom line won't be helped, but millions of people across the world will.